Indicators of responsiveness to immune checkpoint inhibitors

[1]  M. Tiemann,et al.  Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors , 2019, Cancers.

[2]  A. Giobbie-Hurder,et al.  A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma , 2016, Cancer medicine.

[3]  Scott B. Dewell,et al.  Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. , 2016, Molecular cell.

[4]  J. Parker,et al.  An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome , 2016, Nature Medicine.

[5]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[6]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[7]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[8]  Nathan L. Avaritt,et al.  Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma* , 2015, Molecular & Cellular Proteomics.

[9]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[10]  J. Taube,et al.  PD-1/PD-L1 inhibitors. , 2015, Current opinion in pharmacology.

[11]  Michael Lee,et al.  BRAF inhibitor PLX4720 in two BRAF inhibitor-resistant cells, indicating a positive role for Spry2 in the growth inhibition induced by BRAF inhibitors. On the other hand, long-term treatment with PLX4720 induced pERK reactivation following BRAF inhibition in A375P , 2015 .

[12]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[13]  R. Dummer,et al.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors , 2015, Nature Communications.

[14]  M. Askarian-Amiri,et al.  Epigenetic regulation in human melanoma: past and future , 2015, Epigenetics.

[15]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[16]  S. Capaccioli,et al.  CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells. , 2014, The Journal of investigative dermatology.

[17]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[18]  S. McKeown,et al.  Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma , 2014, Oncotarget.

[19]  C. Scheel,et al.  Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer , 2014, Oncotarget.

[20]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[21]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[22]  C. Gedye,et al.  The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel , 2013, Pigment cell & melanoma research.

[23]  B. Baguley,et al.  Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines , 2013, Front. Genet..

[24]  Nathan L. Avaritt,et al.  Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma. , 2013, Journal of proteomics & bioinformatics.

[25]  K. Semba,et al.  CXCL17 Expression by Tumor Cells Recruits CD11b+Gr1highF4/80− Cells and Promotes Tumor Progression , 2012, PloS one.

[26]  F. Meyskens,et al.  NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. , 2012, The Journal of investigative dermatology.

[27]  Ash A. Alizadeh,et al.  The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses , 2012, The Journal of experimental medicine.

[28]  Nathan L. Avaritt,et al.  A quantitative proteomic analysis of FFPE melanoma , 2011, Journal of cutaneous pathology.

[29]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[30]  A. Stromberg,et al.  Prognostic Significance of Tumor Infiltrating Lymphocytes in Melanoma , 2011, The American surgeon.

[31]  C. Slingluff,et al.  Evaluation of molecular markers of mesenchymal phenotype in melanoma , 2010, Melanoma research.

[32]  E. Erdei,et al.  A new understanding in the epidemiology of melanoma , 2010, Expert review of anticancer therapy.

[33]  F. Marincola,et al.  Immunotherapy for Melanoma: Current Status and Perspectives , 2010, Journal of immunotherapy.

[34]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[36]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[37]  D. Rimm,et al.  Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma , 2008, Cancer Epidemiology Biomarkers & Prevention.

[38]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[39]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[40]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[41]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[42]  K. R. Clarke,et al.  Non‐parametric multivariate analyses of changes in community structure , 1993 .

[43]  E. W. Beals,et al.  Bray-curtis ordination: an effective strategy for analysis of multivariate ecological data , 1984 .